





1




2




3



4



5




6




9

10






14



15



16

Asymptomatic PAD

- May self-limit activity to remain below ischemic threshold to avoid leg pain.
- Majority of asymptomatic PAD develop symptoms during an objective walking test despite not reporting any exertional leg symptoms
- Functional impairment comparable to patients with claudication (chronic symptomatic)
- Associated with increased risk of major adverse cardiac events, including mortality

Peripheral Arterial Disease: Diagnosis and Management | PVC 2026

17

What is intermittent claudication?

Table 4. Classical symptoms of intermittent claudication, modified from Rose.⁸¹

Exertional leg pain that:

- Does not begin at rest
- Involves the calf, thigh and/or buttock
- Causes the patient to reduce their walking speed or stop walking
- Resolves within 10 minutes of rest

Peripheral Arterial Disease: Diagnosis and Management | PVC 2026

18

HISTORY

Family history of CVD (coronary artery disease, cerebrovascular disease, aortic aneurysm, LEAD), and premature CVD (fatal or non-fatal CVD event or/and established diagnosis of CVD in first degree male relatives before 55 years or female relatives before 65 years).

Personal history of:

- Hypertension
- Diabetes
- Dyslipidaemia
- Smoking (present and/or past), passive smoking exposure
- Prior CVD
- Chronic kidney disease
- Sedentary life
- Dietary habits
- History of cancer radiation therapy
- Psycho-social factors

Transient or permanent neurological symptoms

Arm exertion pain, particularly if associated with dizziness or vertigo

Symptoms suggesting angina, dyspnoea

Abdominal pain, particularly if related to eating and associated with weight loss

Walking impairment/claudication:

- type: fatigue, aching, cramping, discomfort, burning
- location: buttock, thigh, calf, or foot
- timing: triggered by exercise, uphill rather than downhill, quickly relieved with rest; chronic
- distance

Lower limb pain (including foot) at rest, and evolution at upright or recumbent position

Poorly healing wounds of the extremities

Physical activity assessment:

- Functional capacity and causes of impairment

Erectile dysfunction

CVD = cardiovascular disease; LEAD = lower extremity artery disease.

Peripheral Arterial Disease: Diagnosis and Management | PVC 2026

19

TABLE 7 Alternative Diagnosis for Leg Pain or Claudication Not Related to PAD (Normal Physiological Testing)						
Condition	Location	Characteristic	Effect of Exercise	Effect of Rest	Effect of Position	Other Characteristics
Hip arthritis	Lateral hip, thigh	Aching discomfort	After variable degree of exercise	Not quickly relieved	Improved when not bearing weight	Symptoms variable; history of degenerative arthritis
Foot/ankle arthritis	Ankle, foot, arch	Aching pain	After variable degree of exercise; may also be present at rest	Not quickly relieved	May be relieved by not bearing weight	Symptoms variable
Nerve root compression	Radiates down leg	Sharp lancinating pain	Induced by sitting, standing, or walking (variable)	Often present at rest	Improved by change in position	History of back problems worse with sitting; relief when supine or standing
Spinal stenosis (eg, degenerative disc disease or tumor)	Often bilateral buttocks, posterior leg	Pain and weakness	May mimic claudication	Variable relief but can take a long time to recover	Relief by lumbar spine flexion	Worse with standing and extending spine
Symptomatic popliteal (Baker's) cyst	Behind knee, down calf	Swelling, tenderness	With exercise	Also present at rest	None	Not intermittent
Venous claudication	Entire leg, worse in calf	Tight, bursting pain	After walking	Subsides slowly	Relief speeded by leg elevation	History of iliofemoral deep vein thrombosis edema; signs of venous stasis
Chronic compartment syndrome	Calf muscles	Tight, bursting pain	After strenuous exercise (jogging)	Subsides very slowly	Relief with rest	Typically heavy muscled athletes

20

Table 5. Potential differential diagnostic alternatives causing lower limb pain, that may either present with intermittent claudication symptoms or be misclassified as intermittent claudication.						
Condition	Location	Characteristics	Effect of exercise	Effect of rest	Effect of position	
Baker's cyst	Behind knee	Swelling behind knee and distally. When ruptured, tenderness and calf pain	Worsening of symptoms	None	None	
Deep vein thrombosis and venous claudication caused by chronic venous obstruction	Entire lower limb	Episodic swelling, heaviness, worse in calf	Worsening of symptoms	Subsides slowly	Relief by elevation	
Thromboangiitis obliterans - Buerger's disease	Often bilateral	Young age smokers, pain (most commonly) located in the feet	Worsening of symptoms	Relief with rest	Worse with elevation	
Spinal cord stenosis	Often bilateral buttock and lower limbs	Pain, weakness, numbness	May mimic claudication	Variable relief and may take a long time to recover	Relief with lumbar spine flexion	
Nerve root compression	Radiates down along the posterior aspect of the lower limb	Sharp pain	Induced mainly by standing and walking	Improved by change in position		
Hip arthritis	Ipsilateral lower limb - thigh	Pain and discomfort	Worse with exercise	Relief but it takes time	Less symptoms when not weight bearing	
Foot or ankle arthritis	Ankle or foot	Pain and discomfort	Worse with exercise	Relief but it takes time	Fewer symptoms when not weight bearing or related to activity level	
Chronic exertional compartment syndrome	Lower limb	Pain, swelling, disability	Worse with exercise	Pain even at rest, relief takes time	Worsening or improvement according to position	
Popliteal artery entrapment syndrome	Lower limb	Cold feet after exercise Tingling or burning in calf	Worse with exercise	Relief with rest	Position of foot results in worsening of symptoms	
Cystic adventitial degeneration of the popliteal artery	Calf, always unilateral	Exercise induced pain and discomfort, most common in younger patients	Worse with exercise	Relief with rest	None	
Lymphangitis or cellulitis	Entire lower limb, mostly in calf	Ipsilateral pitting edema, worse in calf	Heaviness	None	None	

21

Table 2.2 • Rutherford classification of the severity of PAD		
Grade	Category	Description
0	0	Asymptomatic
I	1	Mild claudication
I	2	Moderate claudication
I	3	Severe claudication
II	4	Ischaemic rest pain
II	5	Minor tissue loss
III	6	Major tissue loss

22

Rutherford classification for chronic limb ischaemia 1997

is preferred. Walking for 5 minutes at a treadmill speed of 2 mph (176 ft/min) is roughly equivalent to walking three blocks (900 ft) at average speed.

Convert units

Length

900

Foot

=

274.32

Meter

AP, Ankle pressure; PVR, pulse volume recordings; TP, toe pressure.

*Grades II and III, categories 4-6.

†Five minutes at 2 mph on a treadmill.

FORMULA for an approximate result, divide the length value by 3.2808399

23

Table 6. The Fontaine and the revised Rutherford peripheral arterial disease classifications.					
Fontaine		Rutherford			
Class	Symptoms	Grade	Category	Symptoms	Objective criteria
Stage I	Asymptomatic	0	0	Asymptomatic	Normal treadmill or reactive hyperaemia test
Stage II	Claudication pain in limb IIA: Claudication at a distance $\geq$ 200 m IIB: Claudication at a distance $<$ 200 m	I	1	Mild claudication	Completes treadmill exercise; AP after exercise $>$ 50 mmHg but at least 20 mmHg lower than resting value
			2	Moderate claudication	Between categories 1 and 3
			3	Severe claudication	Cannot complete standard treadmill exercise, and AP after exercise $<$ 50 mmHg
Stage III	Rest pain, mostly in the feet	II	4	Ischaemic rest pain	Resting AP $<$ 40 mmHg, flat or barely pulsatile ankle or metatarsal PVR; TP $<$ 30 mmHg
Stage IV	Ulceration and/or gangrene of the limb	III	5	Minor tissue loss - non-healing ulcer, focal gangrene with diffuse pedal ischaemia	Resting AP $<$ 60 mmHg, ankle or metatarsal PVR flat or barely pulsatile; TP $<$ 40 mmHg
			6	Major tissue loss - extending above transmetatarsal level, functional foot no longer salvageable	Same as category 5

25

Physical examination

- T – active infection?
- BP
- HR – ? AF ? PPM/AICD/CRTD
- LL
 - Tissue loss: Ulcer, Gangrene (wet/dry), New amputation wound
 - Cold, Trophic skin changes
 - Mottling / Paraesthesia / Paralysis
- Peripheral pulses
 - LL
 - UL
- AAA
- Renal bruit
- Carotid pulses/bruit

26

1. Wash your hands

2. Introduce yourself to the patient and explain what you are about to do

3. Palpate carotid pulse for rate and rhythm

4. Listen for carotid bruit

5. Check bilateral arm blood pressure

6. Inspect upper limbs for muscle atrophy, tissue loss, embolic phenomenon, capillary refill

7. Palpate bilateral brachial and radial pulses

8. Cardiac auscultation for arrhythmias and murmurs

9. Expose abdomen

10. Palpate for pulsatile abdominal mass

11. Auscultate abdomen for renal and other bruits

12. Inspect lower limbs for gangrene/ tissue loss/ pallor

13. Palpate feet for difference in skin temperature

14. Elevate limb and check for elevation pallor and dependent rubor

15. Palpate for bilateral femoral, popliteal, posterior tibial and dorsalis pedis pulses

16. Auscultate femoral arteries for bruits

17. Suggest using Doppler to check for pulses and ABI

Carotid pulses

Brachial pulses

Radial pulses

Ulnar pulses

Femoral pulses

Popliteal pulses

Posterior tibial pulses

Dorsalis pedis pulses

Figure 3: Pulse examination of patients with lower extremity peripheral arterial disease.

27

Rating of LL extremity pulses?

++

2+

++

2+

+

0

1+

Rating of Pulses	Clinical Finding
0	Absent
1	Diminished
2	Normal
3	Bounding

28

Investigations

- FBC – infection, anaemia, ?polycythaemia
- RP – renal impairment
- LFT / Lipid panel
- PT/PTT GXM → transfusion required?
- CXR
- ECG, CE/TnT
- TTE
- ABPI/TBI
- Toe pressure
- US Arterial Duplex LL
 - Confirm diagnosis, determine anatomical location and degree of stenosis
 - Routine surveillance after lower limb bypass, stenting
- US LL / UL vein mapping
- CT peripheral angiogram for aortoiliac / CFA disease
- MRA – beware nephrogenic systemic fibrosis in CRF patients
- Laser Doppler/TCOM
- ? XRMRI tro OM

30

ABPI

2. How to measure the ABPI

In supine position, with cuff placed just above the ankle, avoiding wounded zones. After a 5–10 minute rest, the SBP is measured by a Doppler probe (5–10 MHz) on the posterior and the anterior tibial (or dorsal pedal) arteries of each foot and on the brachial artery of each arm. Automated BP cuffs are mostly not valid for ankle pressure and may display overestimated results in case of low ankle pressure. The ABI of each leg is calculated by dividing the highest ankle SBP by the highest arm SBP.

Anterior tibial artery

Doppler

Posterior tibial artery

Brachial artery

31

Ankle-brachial index (ABI)

Toe-brachial index (TBI)

Haemodynamic criteria for PAD

Higher systolic ankle pressure of target leg (posterior tibial or dorsalis pedis artery)

Higher systolic brachial pressure, irrespective of target leg

Borderline ABI

Abnormal low ABI

Normal ABI

Abnormal high ABI

Toe pressure of target leg

Higher systolic brachial pressure, irrespective of target leg


Abnormal low TBI

Normal TBI


32

MANAGEMENT


34



35



36



37

THE LANCET

Articles - Volume 405, Issue 10489, P1580-1593, May 03, 2025

Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial

Mat P Bonaca, MD, PhD, FRCPC, Andrew M. Mosen, MD, PhD, Prof Kim Houlden, MD, PhD, Prof Bernhard Ludvik, MD, PhD, Prof Joakim Nordström, MD, PhD, Chethana Kalinayya Ramesh, MSc, et al. Show more


Novo Nordisk A/S: Ozempic® receives EU recommendation in peripheral arterial disease, cementing the broad benefits of semaglutide for people with type 2 diabetes and comorbidities

June 24, 2025 10 min read


Peripheral Arterial Disease: Diagnosis and Management | FVC 2026

STRIDE trial achieved its primary endpoint, with semaglutide 1.0 mg demonstrating a superior and clinically meaningful improvement of 13% in maximum walking distance and a mean treatment difference of 39.9 meters on a steep (12%) incline, compared to placebo at Week 52¹.

38



39



41

Revascularisation for Asymptomatic PAD?

COR	LOE	RECOMMENDATIONS
2a	B-NR	1. In patients with asymptomatic PAD, it is reasonable to perform revascularization procedures (endovascular or surgical) to reconstruct diseased arteries if needed for the safety, feasibility, or effectiveness of other procedures (eg, transfemoral aortic valve replacement, mechanical circulatory support, endovascular aortic aneurysm repair). ¹⁻⁸
3, Harm	B-NR	2. In patients with asymptomatic PAD, revascularization procedures (endovascular or surgical) should not be performed solely to prevent progression of disease. ⁹⁻¹⁶

Peripheral Arterial Disease: Diagnosis and Management | FVC 2020

42

Claudication
(chronic symptomatic PAD)

Symptoms are functionally limiting and response to GDMT (including structured exercise) is inadequate?

YES

NO

Risk-benefit assessment: do potential benefits of revascularization (QOL, walking performance, functional status) outweigh risks? (1)

YES

NO

Revascularization is a reasonable treatment option (2a)

Revascularization is not recommended (3, No benefit)

Peripheral Arterial Disease: Diagnosis and Management | FVC 2020

43

Revascularization is a reasonable treatment option (2a)

Revascularization is not recommended (3, No benefit)

Hemodynamically significant aortoiliac or femoropopliteal disease

Hemodynamically significant common femoral artery disease

Hemodynamically significant isolated infrapopliteal disease

Surgical revascularization is reasonable if perioperative risk is acceptable and technical factors suggest advantages over endovascular approaches (2a)

Endovascular revascularization is effective (1)

Endarterectomy is reasonable, particularly to preserve profunda femoris artery pathways (2a)

Endovascular approaches may be considered if patient is high risk for surgery and/or anatomic factors are favorable (2a)

Effectiveness of endovascular revascularization is unknown (2b)

Effectiveness of surgical revascularization is unknown (2b)

Autogenous vein for femoral-popliteal bypass in preference to prosthetic material (1)

Continue GDMT including structured exercise (1)

Peripheral Arterial Disease: Diagnosis and Management | FVC 2020

44

Aorto-iliac lesions suitable for revascularisation?

Femoropopliteal lesions suitable for revascularisation?

Isolated below knee lesions?

Balloon angioplasty with selective bare metal stent placement should be considered as the primary approach for iliac artery stenoses. (Class I, level A)

Primary bare metal stenting (class I, level B) with self-expanding bare metal stents (Class IIb level B) is recommended for iliac artery occlusions.

Covered stent placement may be considered for TASC II C and D iliac lesions. (Class IIb level B)

Open surgery may be considered for Trans-Atlantic Inter-Society Consensus Document (TASC II C-D) lesions that include the iliac arteries as well as the aorta up to the renal arteries. (Class IIb level B)

Femorofemoral crossover bypass may be considered as an alternative for aorto-iliac lesions in patients who are not suitable for iliac endovascular and/or anatomical surgical revascularisation. (Class IIb level B)

For fit patients with common femoral artery bifurcation stenosis, open surgery is recommended. (Class I, level C)

Endovascular treatment may be considered as an alternative for common femoral artery lesions not extending down to the femoral bifurcation. (Class IIb level B)

Primary bare metal stenting is not recommended over balloon angioplasty with provisional stenting in femoropopliteal lesions. (Class IIb level C)

In patients who have TASC II A or B femoropopliteal lesions, the adjunctive use of paclitaxel-coated balloon angioplasty should be considered after optimal balloon angioplasty without the need for stenting. (Class IIa level A)

Selective drug eluting stent placement should be considered if femoropopliteal plain balloon angioplasty leads to suboptimal results. (Class IIa level B)

Routine use of atherectomy is not recommended in femoropopliteal lesions. (Class III level A)

Covered stents may be considered as an alternative to bare metal stents in the treatment of long (> 20 cm) femoropopliteal lesions. (Class IIb level B)

In patients undergoing femoropopliteal bypass, autogenous vein graft is recommended. (Class I, level A)

In extreme scenarios where endovascular revascularisation of below knee lesions is deemed necessary, balloon angioplasty with selective drug eluting stent placement may be considered. (Class IIb level C)

In the extreme scenario of highly selected patients with intermittent claudication who require stent placement for below knee lesions, the use of drug eluting stents rather than bare metal stents may be considered. (Class IIb level C)

Under extreme circumstances, venous bypass may be considered if exhaustive non-invasive treatment and endovascular therapy is not effective or possible. (Class IIb level C)

Class of recommendation

Is recommended

Should be considered

May be considered

Is not recommended

Peripheral Arterial Disease: Diagnosis and Management | FVC 2020

48

CLTI
CHRONIC LIMB THREATENING ISCHAEMIA

Peripheral Arterial Disease: Diagnosis and Management | FVC 2020

49

CRITICAL LIMB ISCHAEMIA

- Critical limb ischaemia
 - >= 2 weeks duration
 - Ischemic rest pain, ulceration or gangrene
- AND
 - Ankle pressure < 50 mmHg or toe pressure < 20 mmHg
 - ABPI < 0.40
 - ToPO₂ < 30 mmHg
- Fails to encompass the full spectrum of patients who are evaluated and treated in modern practice

OUTDATED

Peripheral Arterial Disease: Diagnosis and Management | FVC 2020

50

CHRONIC LIMB THREATENING ISCHAEMIA

- CLTI = clinical syndrome / wide spectrum of disease
 - >= 2 weeks duration
 - Ischemic rest pain, ulceration or gangrene
 - Objectively documented PAD on haemodynamic testing
- Stage severity of limb threat → risk of major amputation using Wounds, Ischemia, and foot Infection (WIFI) classification

Very low = VL = clinical stage 1

Low = L = clinical stage 2

Moderate = M = clinical stage 3

High = H = clinical stage 4

Clinical stage 5 would signify an unsalvageable foot

51

CLTI
“Arterial cancer”

- End-stage manifestation of systemic atherosclerosis
- Mortality
 - 1 year 24%
 - 5 year 60% ~ 40% survival
 - Stage 3 Colon cancer 28% ~ 72% survival

Charts extracted from Singapore Cancer Registry Annual Report 2021
Published August 2023

Figure 2.2.2 Five-year age-standardised relative survival rate (%) for ten most frequent incident cancers in females, 2017-2021

Neuroendocrine site	94.4
Prostate	88.8
Bladder	82.3
Uterus	71.9
Gastric	63.8
Colon & rectum	62.4
Lymphoid neoplasms	60.9
Ovary	45.0
Breast	41.7
Pancreas	30.3
All sites	13.4

Figure 2.2.3 Five-year age-standardised relative survival rate (%) for ten most frequent incident cancers in males, 2017-2021

Neuroendocrine site	94.2
Prostate	88.9
Kidney	63.4
Colon & rectum	62.7
Lymphoid neoplasms	60.9
Myeloid neoplasms	47.3
Stomach	37.4
Liver	36.0
Lung	19.6
Pancreas	13.1
All sites	13.1

5-year relative survival (%)

52

Component

Score

Description

W

(Wound)

0

No ulcer (ischemic rest pain)

1

Small, shallow ulcer on distal leg or foot without gangrene

2

Deeper ulcer with exposed bone, joint or tendon & gangrenous changes limited to toes

3

Extensive deep ulcers full thickness heel ulcer & callosal involvement & extensive gangrene

I

(Ischaemia)

ABI

>0.90

Arteria pressure (mmHg)

>100

Toe pressure or TdPO₂

>60

1

0.60-0.79

70-100

40-59

2

0.40-0.59

50-70

30-39

3

<0.40

<50

<30

fi

(foot Infection)

0

No symptoms/signs of infection

1

Local infection involving only skin and subcutaneous tissue

2

Local infection involving deeper than skin/subcutaneous tissue

3

Systemic inflammatory response syndrome

Estimate risk of amputation at 1 year for each combination*

	Ischaemia - 0				Ischaemia - 1				Ischaemia - 2				Ischaemia - 3			
W-0	VL	VL	L	M	VL	L	M	H	L	L	M	M	L	M	M	H
W-1	VL	VL	L	M	VL	L	M	H	L	M	H	H	M	M	H	H
W-2	L	L	M	H	M	M	H	H	M	H	H	H	H	H	H	H
W-3	M	M	H	H	H	H	H	H	H	H	H	H	H	H	H	H
	R-0	R-1	R-2	R-3	R-0	R-1	R-2	R-3	R-0	R-1	R-2	R-3	R-0	R-1	R-2	R-3

53

54


55

56


HTTPS://SPECTRUM-SURGERY.COM

DR. TAY JIA SHENG


8




57




63




64




65




66




67




68




69




70




71




72




73




74




75




76



78



79



80

CONTRAST INDUCED NEPHROPATHY

Box 2.1 • Risk factors for contrast-induced nephropathy (CIN) identified in multivariable analysis

- Chronic kidney disease (stage 3 or greater: eGFR <60 mL/min/1.73 m²)
- Diabetes mellitus (type 1 or 2)
- Volume depletion
- Nephrotoxic drug use (NSAIDs, ciclosporin, aminoglycosides)
- Preprocedural haemodynamic instability
- Other comorbidities:
 - Anaemia
 - Congestive heart failure
 - Hypoalbuminaemia

eGFR, estimated glomerular filtration rate; NSAIDs, non-steroidal anti-inflammatory drugs.

- Intra-arterial administration of iodinated contrast poses greater risk of CIN than intravenous administration
- Withhold metformin
 - 2 days before and after
 - Recheck Cr 48hrs KIV restart if <25% increase compared to baseline
- Intravenous volume expansion
 - 1-1.5mL/kg/hr x 3-12 hours before and continue 6-24 hours afterwards
 - Insufficient data for oral fluids
- No role for N-acetylcysteine or sodium bicarbonate drip

Peripheral Arterial Disease: Diagnosis and Management | FVC 2020

81

The diagram illustrates the 'iceberg' epidemiology of lower limb peripheral arterial disease (PAD). The water level represents the threshold for clinical diagnosis. Below the water (undiscovered) is 'Asymptomatic peripheral arterial disease'. Above the water (discovered) are 'Intermittent claudication (IC)' and 'Chronic limb threatening ischaemia (CLTI)' (Gangrene, ulcer, rest pain). The diagram also shows 'Hospital care' and 'Invasive' treatments for CLTI, and 'Conservative' treatments for IC. A vertical axis on the left indicates 'Primary care' and 'Undiagnosed' levels.

Figure 3. Schematic illustration of the lower limb peripheral arterial disease (PAD) iceberg epidemiology, indirectly illustrating the real challenges associated with reaching out to the entire patient population with any healthcare intervention. (Modified after Sogaard et al. Vasa. 2023;52:77-80.)

82

The diagram shows the 'Lifestyle of peripheral arterial disease (PAD)' as a progression from 'Asymptomatic' to 'Intermittent claudication' to 'Chronic limb threatening ischaemia'. It highlights the role of 'Antithrombotic therapies' and 'Revascularisation'. A box lists 'Preventive medicine' interventions: Smoking cessation, Antihypertensive therapies, Lipid lowering therapies, Treatment of diabetes & pre-diabetes, Healthy diet, Supervised/home based exercise, Prevention & medical treatment, and Education & awareness.

Figure 16. The lifestyle of peripheral arterial disease and the value of preventive medicine.

83

CLINICAL VIGNETTE

Peripheral Arterial Disease: Diagnosis and Management | FVC 2020

84



85



86



87



88

Clinical Deterioration

- Staph aureus clusters
- Midfoot osteomyelitis

Due to

- Tibial artery reocclusions
 - Up to 70% reocclusion within 6 months
 - Repeat revascularisation
- Ultrasonic wound debridement + Wound care
- Antibiotics

89

Veraflo Granudacyn Cleanse Choice (VGCC)

90



91



92

MY PAD LIMB SALVAGE pathway

Revascularisation as per best practice

Minor amputations/debridement in OT until no necrotic tissue

Negative Pressure Wound Therapy with instillation and dwell time (NPWT-i)

• Reticulated open-cell foam (ROCF) dressing (V.A.C. Veraflow Cleanse Choice)

Urgostart Contact


Integra dermal regeneration template

AccelHeal electrical stimulation therapy

Negative Pressure Wound Therapy

Urgostart


SSG



93

Tibial Transverse Transport

- Based on Ilizarov's "tension-stress rule" and "natural rebuilding regeneration theory"
- Tissue regeneration via
 - Microvascular neorevascularisation
- By ceaseless and slow transfer to generate a stimulation for local tension using an external fixator



Journal of Inflammation Research

ORIGINAL RESEARCH

Tibial Cortex Transverse Transport Facilitates Severe Diabetic Foot Wound Healing via HIF-1α-Induced Angiogenesis

Jie Liu^{1*}, Xuejie Huang^{1*}, Hongjie Su¹, Jie Yu¹, Xinyu Nie¹, Kaibing Liu¹, Wencong Qin¹, Yongqun Zhao¹, Yongfeng Su¹, Xiaorong Kuang², Di Chen², William W Lu³, Yan Chen¹, Qihai Hu¹

¹Department of Bone and Joint Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, People's Republic of China; ²Nalei Campus of Guangxi Medical University, Nalei, Guangxi, People's Republic of China; ³Research Center for Chaperone-Assisted Drug Discovery, Research Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, People's Republic of China; ⁴Department of Orthopedics and Traumatology, The University of Hong Kong, Pokfulam, Hong Kong

These authors contributed equally to this work

*Correspondence: Jie Chen (Jie Chen, Department of Bone and Joint Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, People's Republic of China, Email: chenjie1980@163.com; Tel: 18678826666)

95

FRONTLINE VASCULAR CARE 2026





Question & Answer



Dr. Tay Jia Sheng

MBBS (Singapore), M.Med (Surgery), FRCSEd (Gen Surg), FAMS

MCR No. M117729


Vascular, Endovascular & General Surgeon

COMFORT. FAIRNESS. VALUE.

96

HANDOUTS ON WEBSITE

<https://spectrum-surgery.com>



97

HTTPS://SPECTRUM-SURGERY.COM

DR. TAY JIA SHENG

14